Come to think of it Refresher, the 72 ex-vivo live tumours tested since 04 in the USA were to make sure that SBP chose the correct target cancers for the first phase 2 trials. That he has chosen to give Coramsine to a RCC patient is what you would expect, given the first phase 2 trial is to be on RCC.
SBP
solbec pharmaceuticals limited
solbecs coramsine wins tick from us doctor, page-8
Add to My Watchlist
What is My Watchlist?